Bang Yu Bai

Solopharm has been operating its own R&D department since 2014. It provides full cycle pharmaceutical development: from an idea to the implementation of a technology into production. #solopharm #pharma #development #research #researchanddevelopment #production #technology

8

Acadia Pharmaceuticals Inc. completes $150M sale of Priority Review Voucher💰 Know complete story - https://lnkd.in/dCbFQDWn Hepion Pharmaceuticals ends merger with Pharma Two B Ltd.🚫 Know complete story - https://lnkd.in/dMSS58Tb Monte Rosa Therapeutics partners with Novartis on MGDs🔬 Know complete story - https://lnkd.in/d4jxZq9D PRT2527 shows early promise in treating lymphoid malignancies🩺 Prelude Therapeutics  Know complete story - https://lnkd.in/dTYRD93F #Acadia #PRVSale #Hepion #PharmaMerger #MonteRosa #Novartis #MGDs #PRT2527 #LymphoidMalignancies

1

🚀 Introducing Dr. Dawaye A Georgewill, Ph.D.: ARSI Canada’s Lead Consultant for Formulation & Process Development! We’re thrilled to welcome Dr. Georgewill to the ARSI team! With 25+ years in formulation and process development, he specializes in scaling solid and semi-solid dosage forms from lab to commercial scale. His expertise will help our clients achieve efficient, high-quality solutions tailored to their unique development challenges. Here’s how Dr. Georgewill and our consulting team can support your drug development journey: ✅ IP Evaluation: Navigate commercialization smoothly with IP and freedom-to-operate (FTO) analyses. ✅ R&D Formulation: Custom solutions to optimize stability, bioavailability, and delivery. ✅ Process Development: Scalable processes from lab to pilot scale, including specialized techniques like spray-drying. ✅ Pivotal Batch Scale-Up: Ready-to-submit exhibit batches for regulatory success. ARSI Canada’s consulting services are designed to meet the needs of biotech, pharma, academia, and specialty chemical industries. Whether overcoming early-stage challenges or preparing for commercial production, we’re here to help you succeed. 🌍 Curious to learn how we can support your goals? Discover our consulting services here: https://lnkd.in/g-KbbDZk Let’s turn your challenges into achievements together! 💼💡 #FormulationDevelopment #ProcessDevelopment #DrugDevelopment

8

Qeen Biotechnologies is proud to have been part of the Canadian delegation to Germany during Bio Europe 2024! This trip provided incredible opportunities to connect with leading German biotech companies and visit industry giants like Bayer. As a global leader in bacteriophage therapy, we are excited to share that our GMP manufacturing suites are ready to produce APIs for Phase 1 and 2 clinical studies, with batch sizes up to 200L. Collaborating internationally is key to advancing innovative solutions, and we look forward to fostering these new partnerships. #QeenBiotechnologies #BioEurope2024 #CanadianDelegation #BacteriophageTherapy #GMPManufacturing #PhageTherapy #APIManufacturing

7

New Health Canada Foreign Actions Reporting Requirements Got You Scrambling? Starting Oct 28, PV teams in Canada must report foreign actions via FDA gateway following REP – and many are struggling to keep up with the sudden changes.   💡 Join us at our DIA Canada booth on Nov 14-15 to see how ZENITH PV can make Foreign Actions Reporting automatic and easy. Our solution enables real-time alerts from global regulatory agencies, transforming foreign action reporting into a seamless, hands-free process. Stop by Zenith PV booth for: 🔹10-Min Rapid Consult to answer your compliance questions 🔹 Interact with our Founder, Manar Hammood or our team and see how you can be ready for this change Contact us to secure a time slot at [email protected] #DIACanada #pharmacovigilance #HealthCanada #CESG #RegulatoryCompliance #ZenithPV

12

Members of the Nanoscope Therapeutics Inc. leadership team will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024. Participating will be CEO & Co-Founder Sulagna Bhattacharya, President & Co-Founder Samarendra Mohanty, Chief Medical Officer Samuel B Barone, MD, CFO Michael Marquez and VP Strategy & Business Development Jared Stephens. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information visit nanostherapeutics.com #biotechnology #ophthalmology #genetherapy https://lnkd.in/gJkhm4d3

84

2 Comments

CPDC is delighted to be featured in the latest issue of BIOTECanada's Insights Magazine, where our work in advancing global radiopharmaceuticals is showcased. Since our founding in 2008, CPDC has been a leader in the radiopharma space, creating innovative technologies and fostering the growth of companies like Fusion Pharmaceuticals, ARTMS, and AtomVie Global Radiopharma Inc. Through partnerships and cutting-edge research, we continue to drive forward the development of diagnostic and therapeutic radiopharmaceuticals, positioning Canada as a global leader in the industry. Read the full article here to learn more about CPDC’s vision and future in radiopharma: https://lnkd.in/g_6T_5eE #CPDC #Radiopharmaceuticals #Innovation #LifeSciences #BIOTECanada #GlobalImpact #Biotech #NuclearMedicine

30

📆 Join Reorg on July 10, 2024, at 2 p.m. ET for an in-depth analysis of Bausch Health Companies Inc.'s strategies to navigate its impending maturity wall, especially in the wake of recent patent developments for its blockbuster drug, Xifaxan. We'll also explore the potential impact of Bausch's financial restructuring on the future disposition of its stake in B+L. Don't miss this critical discussion—register now! https://ow.ly/9cM350SxTqY #FinanceWebinar #PharmaIndustry #FinancialRestructuring

14

INESSS, Quebec HTA, makes WRONG gene therapy recommendation. Twice, Quebec HTA INESSS has diverged from Canada’ Drug Agency HTA committee POSITIVE recommendations for gene therapies, Beqvez and Hemgenix, for treatment of haemophilia B. INESSS agrees safety and efficacy from clinical trials are acceptable. CDA assessing same data recommends drug plans fund while continuing to monitor. This is the right decision and hopefully will allow Canadian patients with haemophilia to have access and open door for gene therapies for other conditions Link to the article: https://lnkd.in/g4EfgG6a

28

1 Comment

While public drug programs across Canada have adopted biosimilar transition or “switching” policies to help sustain their drug plans and expand coverage for innovative new treatments, private market adoption of biosimilars has been slower.   That's why Biosimilars Canada is launching its new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans.   “As cost pressures continue to increase for all businesses, expanding the use of biosimilars should not be overlooked as an important solution to help employers sustain their drug programs and transform the benefits they provide for their employees,” explains Jim Keon, President of Biosimilars Canada.   Learn more about the campaign, and find out how private drug plans can #SaveBigWithBiosimilars. Read the press release here: https://lnkd.in/e3jWubPg Read the campaign page here: https://lnkd.in/eSXCCz8D #GlobalBiosimilarsWeek #GBW24

37

“It’s a scientist’s dream to have something you worked on be approved.” – Dr. Nina E. Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks. Nina shares the journey of innovation, teamwork, and dedication in the development of our recent FDA-approved therapy designed with our Azymetric™  platform. This milestone is a testament to the incredible passion and collaboration of our team as we strive to make a meaningful difference in the lives of patients with difficult-to-treat diseases.. Watch the story and join us in celebrating this milestone! #Biotech #Innovation

166

9 Comments

Yesterday, our SVP Shelita Dattani, PharmD met with Dani Saad from the PMO to discuss National Pharmacare, highlighting our shared goals of improving access to prescription medications for Canadians and protecting the patient care and services that pharmacists provide. All Canadians should have access to drug coverage, whether through public or private prescription drug plans. Any new Pharmacare plan should prioritize caring for uninsured individuals and providing coverage for those who need it most, such as individuals with rare diseases who often face exceptionally high drug costs. We will continue to emphasize the crucial contribution of community pharmacy in the dialogue shaping National Pharmacare, ensuring that the voices of pharmacies and their teams are heard and that Canadians receive the comprehensive drug coverage they need. #NationalPharmacare #Advocacy #BillC64

24

1 Comment

Product Citation: A remarkable multi-institution study conducted by ABL Bio Inc., Sanofi, University of Southern California, UC San Diego & National Research Council Canada / Conseil national de recherches Canada utilized StressMarq's #AlphaSynuclein PFFs to investigate a next-generation bispecific antibody that preferentially binds αSyn aggregates and prevents their seeding capacity in vivo and in vitro. αSyn: https://bit.ly/48w0J27 Full paper: https://bit.ly/4991kbY

6

Pharma Industry News Highlights 🌟💉 1. Telix Pharmaceuticals Limited faces FDA issues with the BLA for TLX250-CDx; plans resubmission in 90 days. 🏥⚖️ 2. Celltrion Inc's Steqeyma receives approval in Canada for treating inflammatory diseases. 🌐✨ 3. 中外製薬 / Chugai Pharmaceutical Co., Ltd. licenses Roche’s inavolisib, expanding their oncology portfolio. 🤝🧬 Stay informed with Pharma Now! Read more news at - https://lnkd.in/dh36nZ8Y What are your thoughts on these updates? Share your opinions in the comments below! 💬✨ #PharmaNow #PharmaNews #HealthcareInnovation #GlobalPharma #FDAApproval #Licensing #Oncology #DrugDevelopment

1

📢 𝗔𝘀𝘁𝗲𝗹𝗹𝗮𝘀 𝗣𝗵𝗮𝗿𝗺𝗮’𝘀 𝗩𝗲𝗼𝘇𝗮𝗵 𝗴𝗲𝘁𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗮𝗻𝗮𝗱𝗮 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗮𝘀 𝗳𝗶𝗿𝘀𝘁 𝗮𝗻𝗱 𝗼𝗻𝗹𝘆 𝗻𝗼𝗻-𝗵𝗼𝗿𝗺𝗼𝗻𝗮𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗩𝗠𝗦 𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗺𝗲𝗻𝗼𝗽𝗮𝘂𝘀𝗲 🩸 Astellas Pharma Canada has received Health Canada approval for 𝗩𝗲𝗼𝘇𝗮𝗵 (𝗳𝗲𝘇𝗼𝗹𝗶𝗻𝗲𝘁𝗮𝗻𝘁), a non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. 💊 VMS includes hot flashes and night sweats, which are the most common and often the most troublesome symptoms of menopause. Menopause can affect up to 40% of a woman's life and brings various physical changes. ⚕️ 𝗕𝗥𝗜𝗚𝗛𝗧 𝗦𝗞𝗬 𝗧𝗿𝗶𝗮𝗹𝘀: • SKYLIGHT 1 and 2 were pivotal trials enrolling over 1,000 women with moderate to severe VMS. Double-blinded and placebo-controlled for the first 12 weeks, followed by a 40-week treatment extension. Women were enrolled at over 180 sites across the US, Canada, and Europe. • SKYLIGHT 4: A 52-week double-blinded, placebo-controlled study designed to assess the long-term safety of fezolinetant. • Fezolinetant in Breast Cancer: Fezolinetant is being investigated for the treatment of moderate to severe VMS in women with breast cancer undergoing adjuvant endocrine therapy. • HIGHLIGHT 1: A randomized, placebo-controlled, double-blind Phase 3 clinical study focusing on fezolinetant’s efficacy and safety for treating moderate to severe VMS in women with hormone receptor-positive breast cancer. The study will measure change in frequency and severity of VMS at weeks 4 and 12, with treatment for 52 weeks and final evaluation at 55 weeks. Keep track of the latest developments in clinical trials and regulatory compliance with expert-driven insights with Innovate Research. #CRO #Innovation #Pharmaceuticals #Biotechnology #PublicHealth #SME #DrugDiscovery #PharmaInnovation #ClinicalResearch #Biotech #Healthcare #SafetyEvaluation #Veozah #HealthCanada #NonHormonalTreatment #VMS #Menopause #VasomotorSymptoms #HotFlashes #NightSweats #MenopauseCare #WomenHealth #AstellasPharma #MenopauseAwareness #HormoneFreeTreatment #HealthInnovation #MenopauseSupport

17

Say goodbye to cryo-freezing with Zymo Research Corp's DNA/RNA Shield reagent.🧬 This advanced DNA and RNA stabilization solution ensures genetic integrity and expression profiles are preserved at ambient temperatures while completely inactivating infectious agents like viruses, bacteria, fungi, and parasites. Protect your samples from freeze-thaw degradation and unexpected freezer failures with confidence. Ready to simplify your workflows? Learn more today! For inquiries, contact us at [email protected]. Visit our website at biomediaholdings.com. #DNA #RNA #Stabilization #MolecularBiology #ResearchSolutions #ZymoResearch #SPDScientific #SamplePreservation #LaboratorySolutions #LifeSciences #ResearchInnovation #GeneticIntegrity #Biotech #LabEssentials

11

🇨🇦 British Columbia becomes the #first #province in #Canada to sign a #pharmacare agreement with the federal government that will help fund hormone replacement therapy and #diabetes expenses. 💊💉 📅🏛️Federal #Health #Minister Mark Holland says B.C.'s portion of the $1.5-billion national plan is estimated to be $195 million, and under the memorandum of understanding, funding could begin by April once the legislation makes it through the Senate. The coverage was initially meant for birth control and diabetes drugs and supplies, but B.C. #Health #Minister Adrian Dix notes that oral contraceptives are already covered under a provincial program. 🚼💊 So, that share will now be used to cover #HRT for women. ♀️🔄 🚼💊Dix says about 150,000 British Columbians receive diabetes medications, and it's estimated that covering hormone replacement therapy will benefit 40,000 women. 👩‍⚕️📈 In April 2023, B.C. became the first jurisdiction in Canada to provide free birth control. https://lnkd.in/g3e2BqRi

5